Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at Upcoming Investor Conferences

aTyr Pharma to present at upcoming investor conferences.
May 02, 2024 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update

aTyr Pharma announces first quarter 2024 results and provides corporate update
April 01, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Participate in April Investor Conferences

aTyr Pharma to Participate in April Investor Conferences
March 14, 2024 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
February 28, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
February 21, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants

Tyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
January 29, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity

aTyr Pharma to present posters on the importance of Neuropilin-2 in immune regulation at the Keystone Symposia on Myeloid Cell Diversity.
January 18, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor for efzofitimod program in interstitial lung disease (ILD).
November 13, 2023 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its...
November 09, 2023 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update

Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment early in the second quarter of 2024. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD initiated...